Rigel names Anne-Marie Duliege as Chief Medical Officer

Elliott Grossbard retires but will continue advising on NDA filing for fostamatinib

Rigel Pharmaceuticals, a biotechnology firm focused on the development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology, has appointed Anne-Marie Duliege as Chief Medical Officer.

Duliege replaces Elliott Grossbard, who is retiring from the position after 14 years with the company. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).

Duliege has extensive experience in the biopharmaceutical industry, including having held leadership positions in clinical research and development at Genentech and Chiron, and most recently serving as Chief of Strategic Development and Head of Immuno-oncology at ChemoCentryx.

From 2004 to 2013, Duliege was a member of the executive team at Affymax. She ultimately held the position of Chief Medical Officer and Head of Research and Clinical Development at this firm.

You may also like